Aglatimagene besadenovec

BIOLOGICAL4 trials

Sponsors

Candel Therapeutics, Inc.

Conditions

Borderline Resectable Pancreatic AdenocarcinomaNon Small Cell Lung CancerNon-squamous, Non-Small Cell Lung CancerProstate Cancer

Phase 2

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Active, not recruitingNCT02446093

Candel Therapeutics, Inc.Borderline Resectable Pancreatic Adenocarcinoma

Start: 2015-10-31End: 2026-07-31Target: 54Updated: 2024-01-08

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Active, not recruitingNCT02768363

Candel Therapeutics, Inc.Prostate Cancer

Start: 2016-05-31End: 2026-12-31Updated: 2025-07-30

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruitingNCT04495153

Candel Therapeutics, Inc.Non Small Cell Lung Cancer

Start: 2020-10-13End: 2026-12-31Updated: 2025-08-22

Phase 3

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

RecruitingNCT07660094

Candel Therapeutics, Inc.Non-squamous, Non-Small Cell Lung Cancer

Start: 2026-06-15End: 2031-10-22Target: 500Updated: 2026-06-22

Related Papers

Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI.

Journal of Clinical Oncology2024-06-018 citations

CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.

Journal of Clinical Oncology2023-06-012 citations

First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC.

Journal of Clinical Oncology2022-06-015 citations